Research programme: immunological disorders therapy - Baylor Research Institute/Roche
Latest Information Update: 16 Jul 2016
At a glance
- Originator Baylor Research Institute; Roche
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Immunological disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Immunological-disorders in USA
- 07 Dec 2010 Early research in Immunological disorders in USA (unspecified route)